These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11404504)

  • 1. Gemcitabine in advanced pancreatic cancer: a phase II trial.
    Crinò L; Mosconi AM; Calandri C; Corgna E; Porrozzi S; Chiara S; Nobili MT; Tonato M
    Am J Clin Oncol; 2001 Jun; 24(3):296-8. PubMed ID: 11404504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
    J Clin Oncol; 1997 Jun; 15(6):2403-13. PubMed ID: 9196156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine in patients with advanced pancreatic cancer.
    Carmichael J; Fink U; Russell RC; Spittle MF; Harris AL; Spiessi G; Blatter J
    Br J Cancer; 1996 Jan; 73(1):101-5. PubMed ID: 8554969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
    Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
    J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
    Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
    Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
    Ulrich-Pur H; Kornek GV; Raderer M; Haider K; Kwasny W; Depisch D; Greul R; Schneeweiss B; Krauss G; Funovics J; Scheithauer W
    Cancer; 2000 Jun; 88(11):2505-11. PubMed ID: 10861426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
    J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
    Casper ES; Green MR; Kelsen DP; Heelan RT; Brown TD; Flombaum CD; Trochanowski B; Tarassoff PG
    Invest New Drugs; 1994; 12(1):29-34. PubMed ID: 7960602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
    Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
    Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
    Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
    Michael A; Hill M; Maraveyas A; Dalgleish A; Lofts F
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):150-3. PubMed ID: 17355112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
    Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
    Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
    Fuchs CS; Clark JW; Ryan DP; Kulke MH; Kim H; Earle CC; Vincitore M; Mayer RJ; Stuart KE
    Cancer; 2002 Jun; 94(12):3186-91. PubMed ID: 12115351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy].
    Chohno T; Aoki T; Hyuga S; Watanabe R; Matsumoto T; Takemoto H; Takachi K; Nishioka K; Uemura Y; Kobayashi K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1881-3. PubMed ID: 24393953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.